scholarly journals Experience of modern skin care series Atopic® using in atopic dermatitis children

2017 ◽  
Vol 14 (2) ◽  
pp. 76-81
Author(s):  
O G Elisyutina ◽  
A O Litovkina ◽  
E S Fedenko
Keyword(s):  
Immune Response ◽  
Atopic Dermatitis ◽  
Inflammatory Disease ◽  
Skin Care ◽  
Barrier Dysfunction ◽  
Epidermal Barrier ◽  
Endogenous Factors ◽  
Complex Therapy ◽  
Allergic Skin ◽  
Disease Stages

Atopic dermatitis - chronic allergic skin inflammatory disease with genetic predisposition, dysbalance of immune response, dysfunction of an epidermal barrier and influence of various exogenous and endogenous factors. Epidermal barrier dysfunction leads to rising of permeability of a skin for allergens, microbs and nonspecific stimuli, as well as to sensitivity to various external influences. Clinically these implications are shown by skin xerosis symptoms therefore. According to modern clinical guidelines, the moisturizing agents, so called emollients, have to be used at all disease stages. Own data on use of modern skin care series Atopic® in complex therapy of atopic dermatitis patients are presented in the article.

scholarly journals The correction of epidermal barrier dysfunction in atopic dermatitis patients

2016 ◽  
Vol 13 (3) ◽  
pp. 59-64
Author(s):  
O G Elisyutina ◽  
O V Shtyrbul ◽  
E N Zemskaya
Keyword(s):  
Atopic Dermatitis ◽  
Genetic Disorders ◽  
Multifactorial Disease ◽  
Complex Treatment ◽  
Barrier Dysfunction ◽  
Epidermal Barrier ◽  
Endogenous Factors ◽  
Leading Role ◽  
Mechanisms Of Development

Atopic dermatitis is chronic inflammatory multifactorial disease, which has genetic disorders, immune mechanisms of development and is under the ainfluence of a combination of exogenous and endogenous factors. Recently a leading role of the epidermal barrier dysfunction in the pathogenesis of atopic dermatitis was shown. The article presents data about emollient for skin care efficacy - Cetaphil® RESTORADERM, which consists of preceramides and filaggrin breakdown products in complex treatment of atopic dermatitis patients.

ATOPIC DERMATITIS – AN OVERVIEW

2021 ◽  
pp. 40-42
Author(s):  
Jayakar Thomas
Keyword(s):  
Atopic Dermatitis ◽  
Environmental Factors ◽  
Genetic Susceptibility ◽  
Skin Disorder ◽  
Immunosuppressive Treatment ◽  
Skin Lesions ◽  
Skin Care ◽  
Barrier Dysfunction ◽  
Epidermal Barrier ◽  
Topical Corticosteroids

Atopic dermatitis is a chronic relapsing inammatory skin disorder with a complex pathogenesis involving genetic susceptibility, immunologic and epidermal barrier dysfunction, and environmental factors. Pruritus is a primary symptom; skin lesions range from mild erythema to severe lichenication to erythroderma. Diagnosis is by history and examination. Treatments include counseling on appropriate skin care, avoidance of triggers, and topical corticosteroids and immunosuppressants. Control of pruritus and superinfections is also important. Severe cases may require systemic immunosuppressive treatment. Childhood atopic dermatitis frequently resolves or lessens signicantly by adulthood.

scholarly journals The IL-13/periostin/IL-24 pathway causes epidermal barrier dysfunction in allergic skin inflammation

Allergy ◽  
2018 ◽  
Vol 73 (9) ◽  
pp. 1881-1891 ◽  
Author(s):  
Y. Mitamura ◽  
S. Nunomura ◽  
Y. Nanri ◽  
M. Ogawa ◽  
T. Yoshihara ◽  
...  
Keyword(s):  
Skin Inflammation ◽  
Barrier Dysfunction ◽  
Epidermal Barrier ◽  
Allergic Skin

Clinical Insights About Topical Treatment of Mild-to-Moderate Pediatric and Adult Atopic Dermatitis

2019 ◽  
Vol 23 (3_suppl) ◽  
pp. 3S-13S ◽  
Author(s):  
Charles W. Lynde ◽  
James Bergman ◽  
Loretta Fiorillo ◽  
Lyn Guenther ◽  
Jill Keddy-Grant ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Calcineurin Inhibitors ◽  
Skin Condition ◽  
Future Research ◽  
Barrier Dysfunction ◽  
Psychosocial Burden ◽  
Epidermal Barrier ◽  
Topical Corticosteroids ◽  
Topical Calcineurin Inhibitors ◽  
Inflammatory Conditions

Atopic dermatitis (AD) is a chronic inflammatory skin condition, also referred to as atopic eczema, that is identified by itching and recurrent eczematous lesions. It often starts in infancy where it affects up to 20% of children but is also highly prevalent in adults. AD inflicts a significant psychosocial burden on patients and their families and increases the risk of other immune-mediated inflammatory conditions, such as asthma and allergic rhinitis, food allergy, and mental health disorders. It is a lifelong condition associated with epidermal barrier dysfunction and altered immune function. Through the use of emollients and anti-inflammatory agents, current prevention and treatment therapies attempt to restore epidermal barrier function. Acute flares are treated with topical corticosteroids. Topical calcineurin inhibitors (TCIs) and topical corticosteroids (TCSs) are used for proactive treatment to prevent remission. There remains a need and opportunity to improve AD care through future research directed toward an improved understanding of the heterogeneity of the disease and its subtypes, the role of autoimmunity in its pathogenesis, the mechanisms behind disease-associated itch and response to specific allergens, and the comparative effectiveness and safety of therapies.

scholarly journals Barrier-Restoring Therapies in Atopic Dermatitis: Current Approaches and Future Perspectives

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Y. Valdman-Grinshpoun ◽  
D. Ben-Amitai ◽  
A. Zvulunov
Keyword(s):  
Atopic Dermatitis ◽  
Inflammatory Disease ◽  
Clinical Studies ◽  
Skin Barrier ◽  
Future Perspectives ◽  
Barrier Dysfunction ◽  
Gene Encoding ◽  
Promising Strategy ◽  
Topical Treatments ◽  
Barrier Repair

Atopic dermatitis is a multifactorial, chronic relapsing, inflammatory disease, characterized by xerosis, eczematous lesions, and pruritus. The latter usually leads to an “itch-scratch” cycle that may compromise the epidermal barrier. Skin barrier abnormalities in atopic dermatitis may result from mutations in the gene encoding for filaggrin, which plays an important role in the formation of cornified cytosol. Barrier abnormalities render the skin more permeable to irritants, allergens, and microorganisms. Treatment of atopic dermatitis must be directed to control the itching, suppress the inflammation, and restore the skin barrier. Emollients, both creams and ointments, improve the barrier function of stratum corneum by providing it with water and lipids. Studies on atopic dermatitis and barrier repair treatment show that adequate lipid replacement therapy reduces the inflammation and restores epidermal function. Efforts directed to develop immunomodulators that interfere with cytokine-induced skin barrier dysfunction, provide a promising strategy for treatment of atopic dermatitis. Moreover, an impressive proliferation of more than 80 clinical studies focusing on topical treatments in atopic dermatitis led to growing expectations for better therapies.

scholarly journals Epidermal Barrier Dysfunction in Atopic Dermatitis

2021 ◽  
Vol 79 (3) ◽  
pp. 207-216
Author(s):  
Tiago Fernandes Gomes ◽  
Rebeca Calado ◽  
Margarida Gonçalo
Keyword(s):  
Atopic Dermatitis ◽  
Current Knowledge ◽  
Skin Barrier ◽  
Initial Step ◽  
Barrier Dysfunction ◽  
Epidermal Barrier ◽  
Atopic March ◽  
T Helper 2 ◽  
Barrier Repair

Impaired skin barrier is one of the hallmarks of atopic dermatitis (AD), with abnormalities in the cornified envelope, lipid lamellae, tight junctions and cutaneous microbiome. These findings are also present in nonlesional skin of AD individuals, suggesting that epidermal barrier defects may be the initial step towards the development of AD and eventually other atopic diseases (atopic march). It is currently known that pathophysiology of AD involves an interplay between this dysfunctional skin barrier and a predominantly type 2 skewed innate and adaptive immune responses, which further disrupt the skin barrier through type 2 cytokines. In this setting, there is enhanced penetration of environmental and food allergens through a deficient barrier, leading to an increased susceptibility to sensitization. During the sensitization process, thymic stromal lymphopoietin (TSLP) polarizes skin dendritic cells to a T-helper 2 response, and TSLP seems to be a key cytokine in the sensitization of food allergy, allergic asthma and rhinitis. In this review, the authors describe the current knowledge of the pathophysiology of the epidermal barrier, its disruption in AD and how it may be involved in the development of atopic comorbidities and the role of barrier repair therapy on the prevention of the atopic march progression.  

scholarly journals Filaggrin and Atopic Dermatitis: Clinical and Pathogenetic Parallels and Therapeutic Possibilities

2021 ◽  
Vol 20 (5) ◽  
pp. 435-440
Author(s):  
Nikolay N. Murashkin ◽  
Roman A. Ivanov ◽  
Eduard T. Ambarchian ◽  
Roman V. Epishev ◽  
Alexander I. Materikin ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Secondary Infection ◽  
Allergic Diseases ◽  
Structural Components ◽  
Barrier Dysfunction ◽  
Treatment Results ◽  
Significant Treatment ◽  
Epidermal Barrier ◽  
New Class ◽  
Keratin Filaments

Atopic dermatitis (AtD) is multifactorial inflammatory skin disease, one of the aspects of its pathogenesis is epidermal barrier dysfunction. Early development of AtD is associated with filaggrin dysfunction. Filaggrin is a protein involved in aggregation of keratin filaments in the upper layers of epidermis and the retention of lipids and proteins between corneocytes. Frequently, filaggrin dysfunction can be accompanied with secondary infection and high risk of other allergic diseases development. This can happen due to disturbance in terminal differentiation of epidermal cells and, as consequence, malfunction of epidermal barrier. Thus, the long regular use of emollients is the basis of AtD therapy. New class of emollients (“emollents plus”) allowed us to achieve more significant treatment results in patients with AtD. These emollients reduce inflammatory process activity in the skin by replacing structural components of abnormal epidermal barrier.

scholarly journals Epidermal Barrier Dysfunction in Atopic Dermatitis

2009 ◽  
Vol 129 (8) ◽  
pp. 1892-1908 ◽  
Author(s):  
Michael J. Cork ◽  
Simon G. Danby ◽  
Yiannis Vasilopoulos ◽  
Jonathan Hadgraft ◽  
Majella E. Lane ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Barrier Dysfunction ◽  
Epidermal Barrier
Sign in / Sign up

Export Citation Format

Share Document